Cooper R G, Holland J F, Glidewell O
Cancer. 1979 Sep;44(3):793-8. doi: 10.1002/1097-0142(197909)44:3<793::aid-cncr2820440302>3.0.co;2-y.
One hundred women with primary breast cancer with 4 or more metastatic axillary nodes were treated for 9 months postoperatively with vincristine, prednisone, cyclophosphamide, methotrexate, and fluorouracil (VPCMF). Sixty-five women have been observed for a minimum of 5 years or until failure and the rest for 3 years or more. For 73 women who received adjuvant chemotherapy only, observed for 5 1/2 years median, disease-free status by life table analysis is 68% at 8 years. No significance difference was found between response of pre- and postmenopausal women in disease-free interval or survival. Mortality compared to expectation was sharply reduced; only 9 of 73 have died. These findings demonstrate the long term effectiveness of relatively short-term surgical adjuvant combination chemotherapy in pre- and post-menopausal patients with breast cancer at high risk.
100例原发性乳腺癌且腋窝淋巴结转移4个及以上的女性患者在术后接受了9个月的长春新碱、泼尼松、环磷酰胺、甲氨蝶呤和氟尿嘧啶（VPCMF）治疗。65例女性患者被观察了至少5年或直至病情进展，其余患者被观察了3年或更长时间。对于仅接受辅助化疗的73例女性患者，中位观察时间为5.5年，通过生命表分析，8年时无病状态为68%。绝经前和绝经后女性在无病间期或生存率方面的反应未发现显著差异。与预期相比，死亡率大幅降低；73例中只有9例死亡。这些发现证明了相对短期的手术辅助联合化疗对绝经前和绝经后高危乳腺癌患者的长期有效性。
